CytomX Therapeutics

CytomX develops cancer drugs that target tumors while sparing healthy tissue. Its therapies aim to reduce side effects for patients. The company partners with large pharmaceutical firms to advance new treatments.

What’s in the CytomX Toolbox?

• Antibody Drug Conjugates (ADCs): Drugs that deliver toxic agents directly to cancer cells, aiming to limit harm to healthy cells. In 2025, all company revenue came from research collaborations, predominantly related to ADC programs.
• T-cell Engagers (TCEs): Experimental drugs designed to help the immune system find and attack cancer cells. These are in early development and do not yet generate revenue.
• Cytokines: Modified proteins that may boost immune responses against tumors. These are in early clinical trials and preclinical research.
• mRNA-based Therapies: Treatments using messenger RNA to instruct cells to fight cancer, developed with partners. These programs are currently paused and do not contribute to revenue.

Growth Spurts and Strategic Moves

• Formed major partnerships with Bristol Myers Squibb, Amgen, Astellas Pharma, Regeneron, Moderna, and Pfizer from 2015 to 2025.
• Advanced lead drug Varseta-M into Phase 1 trials for colorectal cancer in 2025.
• Restructured in January 2025, reducing workforce by 40% to focus on core programs.
• Raised $93.4 million in a public offering and $16.3 million through equity sales in 2025.
• Signed a new headquarters lease in Emeryville, California, starting October 2026.

Why CytomX Catches the Eye

CytomX’s technology activates cancer drugs only inside tumors, aiming to reduce side effects. Its business model relies on research partnerships with large pharmaceutical companies. The company holds a broad patent portfolio and focuses on targets with high medical need.

Five Things You Need to Know

• Revenue was $76.2 million in 2025, down 44.8% from 2024.
• Net loss was $17.4 million in 2025, compared to $31.9 million net income in 2024.
• Cash and investments totaled $137.1 million at year-end 2025.
• All revenue comes from research collaborations, not product sales.
• Workforce dropped to 69 employees after restructuring in 2025.

Bottom Line

CytomX has shifted focus to its most promising cancer drug programs and partnerships. The company’s future depends on advancing its pipeline and maintaining key collaborations.